• Something wrong with this record ?

Preoperative Chemoradiotherapy for Gastroesophageal Junction Adenocarcinoma Modified by PET/CT: Results of Virtual Planning Study

M. Slavik, P. Burkon, I. Selingerova, P. Krupa, T. Kazda, J. Stankova, T. Nikl, R. Hejnova, Z. Rehak, P. Osmera, T. Prochazka, E. Dvorakova, P. Pospisil, P. Grell, P. Slampa, R. Obermannova

. 2021 ; 57 (12) : . [pub] 20211206

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22003037

Grant support
LM2018128 Ministry of Education, Youth and Sports, Czech Republic
LM2018125 Ministry of Education, Youth and Sports, Czech Republic
17-29389A Ministry of health, Czech Republic

Background and Objectives: The treatment of gastroesophageal junction (GEJ) adenocarcinoma consists of either perioperative chemotherapy or preoperative chemoradiotherapy. Radiotherapy (RT) in the neoadjuvant setting is associated with a higher probability of resections with negative margins (R0) and better tumor regression rate, which might be enhanced by incrementing RT dose with potential impact on treatment results. This virtual planning study demonstrates the feasibility of increasing the dose to GEJ tumor and involved nodes using PET/CT imaging. Materials and Methods: 16 patients from the chemoradiotherapy arm of the phase II GastroPET study were treated by a prescribed dose of 45.0 Gray (Gy) in 25 fractions. PET/CT was performed before treatment. The prescribed dose was virtually boosted on PET/CT-positive areas to 54.0 Gy by 9 Gy in 5 fractions. Dose-volume histograms (DVH) were compared, and normal tissue complication (NTCP) modeling was performed for both dose schedules. Results: DVHs were exceeded in mean heart dose in one case for 45.0 Gy and two cases for 54.0 Gy, peritoneal space volume criterion V45Gy < 195 ccm in three cases for 54.0 Gy and V15Gy < 825 ccm in one case for both dose schedules. The left lung volume of 25 Gy isodose exceeded 10% in most cases for both schedules. The NTCP values for the heart, spine, liver, kidneys and intestines were zero for both schemes. An increase in NTCP value was for lungs (median 3.15% vs. 4.05% for 25 × 1.8 Gy and 25 + 5 × 1.8 Gy, respectively, p = 0.013) and peritoneal space (median values for 25 × 1.8 Gy and 25 + 5 × 1.8 Gy were 3.3% and 14.25%, respectively, p < 0.001). Conclusion: Boosting PET/CT-positive areas in RT of GEJ tumors is feasible, but prospective trials are needed.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003037
003      
CZ-PrNML
005      
20220127150726.0
007      
ta
008      
220113s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/medicina57121334 $2 doi
035    __
$a (PubMed)34946279
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Slavik, Marek $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 57 Brno, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic
245    10
$a Preoperative Chemoradiotherapy for Gastroesophageal Junction Adenocarcinoma Modified by PET/CT: Results of Virtual Planning Study / $c M. Slavik, P. Burkon, I. Selingerova, P. Krupa, T. Kazda, J. Stankova, T. Nikl, R. Hejnova, Z. Rehak, P. Osmera, T. Prochazka, E. Dvorakova, P. Pospisil, P. Grell, P. Slampa, R. Obermannova
520    9_
$a Background and Objectives: The treatment of gastroesophageal junction (GEJ) adenocarcinoma consists of either perioperative chemotherapy or preoperative chemoradiotherapy. Radiotherapy (RT) in the neoadjuvant setting is associated with a higher probability of resections with negative margins (R0) and better tumor regression rate, which might be enhanced by incrementing RT dose with potential impact on treatment results. This virtual planning study demonstrates the feasibility of increasing the dose to GEJ tumor and involved nodes using PET/CT imaging. Materials and Methods: 16 patients from the chemoradiotherapy arm of the phase II GastroPET study were treated by a prescribed dose of 45.0 Gray (Gy) in 25 fractions. PET/CT was performed before treatment. The prescribed dose was virtually boosted on PET/CT-positive areas to 54.0 Gy by 9 Gy in 5 fractions. Dose-volume histograms (DVH) were compared, and normal tissue complication (NTCP) modeling was performed for both dose schedules. Results: DVHs were exceeded in mean heart dose in one case for 45.0 Gy and two cases for 54.0 Gy, peritoneal space volume criterion V45Gy < 195 ccm in three cases for 54.0 Gy and V15Gy < 825 ccm in one case for both dose schedules. The left lung volume of 25 Gy isodose exceeded 10% in most cases for both schedules. The NTCP values for the heart, spine, liver, kidneys and intestines were zero for both schemes. An increase in NTCP value was for lungs (median 3.15% vs. 4.05% for 25 × 1.8 Gy and 25 + 5 × 1.8 Gy, respectively, p = 0.013) and peritoneal space (median values for 25 × 1.8 Gy and 25 + 5 × 1.8 Gy were 3.3% and 14.25%, respectively, p < 0.001). Conclusion: Boosting PET/CT-positive areas in RT of GEJ tumors is feasible, but prospective trials are needed.
650    12
$a adenokarcinom $x diagnostické zobrazování $x terapie $7 D000230
650    _2
$a chemoradioterapie $7 D059248
650    _2
$a gastroezofageální junkce $x diagnostické zobrazování $7 D004943
650    _2
$a lidé $7 D006801
650    12
$a PET/CT $7 D000072078
650    _2
$a prospektivní studie $7 D011446
650    _2
$a plánování radioterapie pomocí počítače $7 D011880
655    _2
$a časopisecké články $7 D016428
700    1_
$a Burkon, Petr $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 57 Brno, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic
700    1_
$a Selingerova, Iveta $u Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 53 Brno, Czech Republic $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic
700    1_
$a Krupa, Pavel $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 57 Brno, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic
700    1_
$a Kazda, Tomas $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 57 Brno, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic
700    1_
$a Stankova, Jaroslava $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 57 Brno, Czech Republic
700    1_
$a Nikl, Tomas $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 57 Brno, Czech Republic
700    1_
$a Hejnova, Renata $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic
700    1_
$a Rehak, Zdenek $u Department of Nuclear Medicine, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 53 Brno, Czech Republic
700    1_
$a Osmera, Pavel $u Department of Nuclear Medicine, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 53 Brno, Czech Republic
700    1_
$a Prochazka, Tomas $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 57 Brno, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic
700    1_
$a Dvorakova, Eva $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 57 Brno, Czech Republic
700    1_
$a Pospisil, Petr $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 57 Brno, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic
700    1_
$a Grell, Peter $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Kamenice 735/5, 625 00 Brno, Czech Republic $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 53 Brno, Czech Republic
700    1_
$a Slampa, Pavel $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 57 Brno, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic
700    1_
$a Obermannova, Radka $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Kamenice 735/5, 625 00 Brno, Czech Republic $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 53 Brno, Czech Republic
773    0_
$w MED00180386 $t Medicina (Kaunas, Lithuania) $x 1648-9144 $g Roč. 57, č. 12 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34946279 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127150722 $b ABA008
999    __
$a ok $b bmc $g 1750720 $s 1154186
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 57 $c 12 $e 20211206 $i 1648-9144 $m Medicina $n Medicina (Kaunas) $x MED00180386
GRA    __
$a LM2018128 $p Ministry of Education, Youth and Sports, Czech Republic
GRA    __
$a LM2018125 $p Ministry of Education, Youth and Sports, Czech Republic
GRA    __
$a 17-29389A $p Ministry of health, Czech Republic
LZP    __
$a Pubmed-20220113

Find record

Citation metrics

Archiving options